We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors.
- Authors
Jin, Ying; Chen, Dong-Liang; Wang, Feng; Yang, Chao-pin; Chen, Xu-Xian; You, Jin-qi; Huang, Jin-Sheng; Shao, Yang; Zhu, Dong-Qin; Ouyang, Yu-Ming; Luo, Hui-Yan; Wang, Zhi-Qiang; Wang, Feng-Hua; Li, Yu-Hong; Xu, Rui-Hua; Zhang, Dong-Sheng
- Abstract
A more common and noninvasive predicting biomarker for programmed cell death 1 (PD-1) antibody remains to be explored. We assessed 46 patients with advanced gastric cancer who received PD-1 antibody immunotherapy and 425-genes next-generation sequencing (NGS) testing. Patients who had a > 25% decline in maximal somatic variant allelic frequency (maxVAF) had a longer progression free survival (PFS) and higher response rate than those who did not (7.3 months vs 3.6 months, p = 0.0011; 53.3% vs 13.3%, p = 0.06). The median PFS of patients with undetectable and detectable post-treatment circulating tumor DNA (ctDNA) was 7.4 months vs. 4.9 months (p = 0.025). Mutation status of TGFBR2, RHOA, and PREX2 in baseline ctDNA influenced the PFS of immunotherapy (p < 0.05). Patients with alterations in CEBPA, FGFR4, MET or KMT2B (p = 0.09) gene had greater likelihood of immune-related adverse events (irAEs). ctDNA can serve as a potential biomarker of the response to immunotherapy in advanced gastric cancers, and its potential role in predicting irAEs worth further exploration.
- Subjects
IMMUNE checkpoint inhibitors; CIRCULATING tumor DNA; STOMACH cancer; CANCER patients; IPILIMUMAB
- Publication
Molecular Cancer, 2020, Vol 19, Issue 1, pN.PAG
- ISSN
1476-4598
- Publication type
Letter
- DOI
10.1186/s12943-020-01274-7